AstraZeneca enters agreement with Recordati for Seloken in Europe
- Details
- Category: AstraZeneca
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe.
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
- Details
- Category: Novartis
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of expanding the use of Zykadia® (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
100 healthy years - are kids prepared?
- Details
- Category: Merck Group
Merck, a leading science and technology company, convened experts from diverse reputable organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the company's headquarters in Darmstadt, Germany, to debate relevant questions such as: What are the most urgent threats to our children's long-term health? What can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
- Details
- Category: Novartis
On World Hypertension Day 2017, the Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities, an innovative initiative to address the high rates of high blood pressure (hypertension) in low-income urban communities.
Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China
- Details
- Category: Boehringer Ingelheim
Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology.
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
- Details
- Category: AstraZeneca
AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
- Details
- Category: Pfizer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) have announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
More Pharma News ...
- SERMO unveils first global physician-to-physician drug ratings tool
- Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering
- Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor
- Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
- Grants4Apps Accelerator and new Dealmaker now open for submissions
- AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
- New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis